Conatus Pharmaceuticals Inc(NASDAQ:CNAT) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Earnings per share were $-0.30. Analysts had estimated an EPS of $-0.38.
Conatus Pharmaceuticals Inc (CNAT) made into the market gainers list on Fridays trading session with the shares advancing 0.51% or 0.01 points. Due to strong positive momentum, the stock ended at $1.97, which is also near the day’s high of $1.99. The stock began the session at $1.95 and the volume stood at 45,589 shares. The 52-week high of the shares is $7.12 and the 52 week low is $1.4. The company has a current market capitalization of $44 M and it has 2,20,85,886 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Apr 10, 2015, Daniel L Kisner (director) purchased 4,000 shares at $5.75 per share price.
Conatus Pharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of medicines to treat liver disease. The Company’s lead compound emricasan is an orally active pan-caspase protease inhibitor designed to reduce the activity of human caspases which are enzymes that mediate inflammation and apoptosis. It is conducting a clinical program to demonstrate the therapeutic benefit of emricasan in patients with chronic liver disease across the spectrum of liver disease including liver cirrhosis (LC); liver cirrhosis with portal hypertension (PH); post-orthotopic liver transplant (POLT) recipients with reestablished liver fibrosis post-transplant as a result of recurrent hepatitis C virus (HCV) infection who have achieved a sustained viral response (SVR) following HCV antiviral therapy (POLT-HCV-SVR) and non-alcoholic fatty liver disease (NAFLD) including patients with inflammatory and/or fibrotic non-alcoholic steatohepatitis (NASH).